莫西沙星四联疗法根除幽门螺旋杆菌的临床疗效观察  

Clinical Efficacy of Moxifloxacin-containing Quadruple Therapy in Eradication of Helicobacter Pylori

作　　者：曾玲[1] ZENG Ling(Department of Gastroenterology,Ganzhou People’s Hospital,Ganzhou Jiangxi 341000,China)

机构地区：[1]赣州市人民医院消化内科,江西赣州341000

出　　处：《中国卫生标准管理》2022年第5期85-88,共4页China Health Standard Management

基　　金：江西省赣州市指导性科技计划项目(GZ2020ZSF217)。

摘　　要：目的 探讨莫西沙星四联疗法根除幽门螺旋杆菌的临床疗效。方法 收集2020年6—12月在医院消化内科确诊幽门螺旋杆菌感染患者,随机分为两组,每组65例。试验组采用口服含莫西沙星四联根除方案(包括莫西沙星、呋喃唑酮、枸橼酸铋钾胶囊、埃索美拉唑镁肠溶胶囊,连续服用14 d);对照组采用常规四联根除方案(包括克拉霉素、呋喃唑酮、枸橼酸铋钾胶囊、埃索美拉唑镁肠溶胶囊,连续服用14 d)。治疗4周后,观察两组患者幽门螺旋杆菌根除率、不良反应发生率、症状缓解率、胃黏膜炎症情况。结果 试验组幽门螺旋杆菌根除率92.3%(60/65),对照组幽门螺旋杆菌根除率72.3%(47/65),症状缓解率分别是96.9%(63/65),78.5%(51/65),不良反应发生率分别是6.2%(4/65),20.0%(13/65),试验组炎症改善情况明显优于对照组,差异有统计学意义(P <0.05)。结论 莫西沙星四联疗法根除幽门螺旋杆菌疗效好,不良反应少,可作为根除幽门螺旋杆菌的优选方案。Objective To explore clinical efficacy of moxifloxacincontaining quadruple therapy in eradication of Helicobacter pylori.Methods Patients with Helicobacter pylori infection in the department of gastroenterology of our hospital from June to December 2020were randomly divided into two groups, 65 cases in each group. The patients in the experimental group were treated with oral moxifloxacin quadruple eradication program(including moxifloxacin, furazolidone,bismuth potassium citrate capsules, esomeprazole magnesium enteric coated capsules, for 14 consecutive days);while the patients in the control group were treated with conventional quadruple eradication program(including clarithromycin, furazolidone, bismuth potassium citrate capsules, esomeprazole magnesium enteric coated capsules, for 14 consecutive days). After 4 weeks of treatment, the eradication rate of Helicobacter pylori, incidence of adverse reactions, remission rate of symptoms and gastric mucosal inflammation were observed. Results The eradication rate of Helicobacter pylori in the experimental group was 92.3%(60/65), while that in the control group was 72.3%(47/65).The remission rate of symptoms was 96.9%(63/65), 78.5%(51/65),and the incidence of adverse reactions was 6.2%(4/65), 20.0%(13/65),respectively. The improvement of inflammation in the experimental group was significantly better than that in the control group, the difference was statistically significant(P < 0.05). Conclusion Moxifloxacin-containing quadruple therapy has good curative effect and less side effects on eradication of Helicobacter pylori, which can be used as the preferred scheme for eradication of Helicobacter pylori.

关 键 词：莫西沙星 四联疗法 幽门螺旋杆菌 疗效 不良反应 炎症 根除率 

分 类 号：R656[医药卫生—外科学]